Trial · NCT05131477
Results by group2,914
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 2,914
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage Change in EASI (Eczema Area and Severity Index) From Baseline to Week 16 (Part 1) | 250 mg (500 mg LD) KY1005 (Part 1) | -61.5 | Standard Error 4.68 | percentage of change | |
| Percentage Change in EASI (Eczema Area and Severity Index) From Baseline to Week 16 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | -56.8 | Standard Error 4.59 | percentage of change | |
| Percentage Change in EASI (Eczema Area and Severity Index) From Baseline to Week 16 (Part 1) | 125 mg KY1005 (Part 1) | -51.6 | Standard Error 4.59 | percentage of change | |
| Percentage Change in EASI (Eczema Area and Severity Index) From Baseline to Week 16 (Part 1) | 62.5 mg KY1005 (Part 1) | -59.6 | Standard Error 4.53 | percentage of change | |
| Percentage Change in EASI (Eczema Area and Severity Index) From Baseline to Week 16 (Part 1) | Placebo (Part 1) | -29.4 | Standard Error 4.76 | percentage of change | |
| Percentage Change in EASI (Eczema Area and Severity Index) From Baseline to Week 24 (Part 1) | 250 mg (500 mg LD) KY1005 (Part 1) | -64.4 | Standard Error 5.17 | percentage of change | |
| Percentage Change in EASI (Eczema Area and Severity Index) From Baseline to Week 24 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | -52.2 | Standard Error 5.14 | percentage of change | |
| Percentage Change in EASI (Eczema Area and Severity Index) From Baseline to Week 24 (Part 1) | 125 mg KY1005 (Part 1) | -53.7 | Standard Error 5.08 | percentage of change | |
| Percentage Change in EASI (Eczema Area and Severity Index) From Baseline to Week 24 (Part 1) | 62.5 mg KY1005 (Part 1) | -54.4 | Standard Error 5.09 | percentage of change | |
| Percentage Change in EASI (Eczema Area and Severity Index) From Baseline to Week 24 (Part 1) | Placebo (Part 1) | -27.6 | Standard Error 5.29 | percentage of change | |
| Percentage of Participants With at Least a 75% Reduction From Baseline in EASI (EASI 75) at Week 16 and Week 24 (Part 1) | 250 mg (500 mg LD) KY1005 (Part 1) | Week 16 | 40.3 | Percentage of participants | |
| Percentage of Participants With at Least a 75% Reduction From Baseline in EASI (EASI 75) at Week 16 and Week 24 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | Week 16 | 38.5 | Percentage of participants | |
| Percentage of Participants With at Least a 75% Reduction From Baseline in EASI (EASI 75) at Week 16 and Week 24 (Part 1) | 125 mg KY1005 (Part 1) | Week 16 | 42.9 | Percentage of participants | |
| Percentage of Participants With at Least a 75% Reduction From Baseline in EASI (EASI 75) at Week 16 and Week 24 (Part 1) | 62.5 mg KY1005 (Part 1) | Week 16 | 40.5 | Percentage of participants | |
| Percentage of Participants With at Least a 75% Reduction From Baseline in EASI (EASI 75) at Week 16 and Week 24 (Part 1) | Placebo (Part 1) | Week 16 | 11.4 | Percentage of participants | |
| Percentage of Participants With at Least a 75% Reduction From Baseline in EASI (EASI 75) at Week 16 and Week 24 (Part 1) | 250 mg (500 mg LD) KY1005 (Part 1) | Week 24 | 54.5 | Percentage of participants | |
| Percentage of Participants With at Least a 75% Reduction From Baseline in EASI (EASI 75) at Week 16 and Week 24 (Part 1) | 250 mg (no LD) KY1005 (Part 1) | Week 24 | 38.5 | Percentage of participants | |
| Percentage of Participants With at Least a 75% Reduction From Baseline in EASI (EASI 75) at Week 16 and Week 24 (Part 1) | 125 mg KY1005 (Part 1) | Week 24 | 49.4 | Percentage of participants | |
| Percentage of Participants With at Least a 75% Reduction From Baseline in EASI (EASI 75) at Week 16 and Week 24 (Part 1) | 62.5 mg KY1005 (Part 1) | Week 24 | 40.5 | Percentage of participants | |
| Percentage of Participants With at Least a 75% Reduction From Baseline in EASI (EASI 75) at Week 16 and Week 24 (Part 1) | Placebo (Part 1) | Week 24 | 17.7 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05131477/results